Premium listings
  • 3rd International Conference on Transcriptomics

    3rd International Conference on Transcriptomics

    Life Sciences Bangkok (Bangkok) March 13, 2017 Check with publisher

    Conference Series has been instrumental in conducting international Biochemistry meetings for seven years, and very excited to expand Europe, America and Asia Pacific continents. Previous meetings were held in major cities like Philadelphia, Orlando ...

  • Developing drugs for the treatment of neurodegenerative diseases

    Developing drugs for the treatment of neurodegenerative diseases

    PhD Studentships Liverpool December 3, 2016 Check with publisher

    Ageing is arguably the major biomedical challenge of the 21st century with the incidence of age-related diseases, and neurodegenerative diseases in particular, expected to increase dramatically in the coming decades. In model organisms, the process o...

  • DrugAge database of compounds that increase lifespan

    DrugAge database of compounds that increase lifespan

    Biomedical Sciences Liverpool August 24, 2015 Check with publisher

    We're starting a new database of drugs and compounds (including natural products) with anti-ageing properties that extend longevity in model organisms. The database will be called DrugAge, and although we have some data already, we are looking for da...

Listings
  • Anti-EpCAM-SPDB-DM4 ADC

    Anti-EpCAM-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-EpCAM monoclonal antibody conjugated via a SPDB linker to DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM...

  • Anti-EpCAM-SMCC-DM1 ADC

    Anti-EpCAM-SMCC-DM1 ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-EpCAM monoclonal antibody conjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM...

  • Anti-EGFR (cetuximab)-SMCC-Doxorubicin ADC

    Anti-EGFR (cetuximab)-SMCC-Doxorubicin ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-EGFR monoclonal antibody (cetuximab) conjugated via a SMCC linker to Doxorubicin. The Doxorubicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endoc...

  • Anti-EGFR-SMCC-Dox ADC

    Anti-EGFR-SMCC-Dox ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-EGFR monoclonal antibody conjugated via a SMCC linker to Dox. The Dox is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, Dox...

  • Anti-EGFR-SMCC-DM1 ADC

    Anti-EGFR-SMCC-DM1 ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-EGFRvIII monoclonal antibody conjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell,...

  • Anti-EGFR (J2898A)-SMCC-DM1 ADC

    Anti-EGFR (J2898A)-SMCC-DM1 ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-EGFR (J2898A) monoclonal antibody conjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the ...

  • Anti-EGFR (J2898A)-SMCC-DM1 ADC

    Anti-EGFR (J2898A)-SMCC-DM1 ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-EGFR (J2898A) monoclonal antibody conjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the ...

  • Anti-EGFR (MAb806)-SMCC-DM1 ADC

    Anti-EGFR (MAb806)-SMCC-DM1 ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-EGFR monoclonal antibody (MAb806) conjugated via a SMCC linker to a DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within th...

  • Anti-EFNA4 (clone huE47)-AcBut-CM ADC

    Anti-EFNA4 (clone huE47)-AcBut-CM ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-EFNA4 monoclonal antibody (clone huE47)) conjugated via an AcBut linker to CM. The CM is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Disu...

  • Anti-EFNA4 (clone huE22)-AcBut-CM ADC

    Anti-EFNA4 (clone huE22)-AcBut-CM ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-EFNA4 monoclonal antibody (clone huE22)) conjugated via an AcBut linker to CM. The CM is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Disu...

  • Anti-CR2 (THB-5)-SPP-DM1 ADC

    Anti-CR2 (THB-5)-SPP-DM1 ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CR2 monoclonal antibody (THB-5) conjugated via a SPP linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cel...

  • Products Used in Early Phase IND Studies

    Products Used in Early Phase IND Studies

    Quality Control, Safety & Security Fremont (California) November 27, 2017 Free

    Overview: How it may be integrated with the recommendations of the guidance documents on CMC requirements. Areas Covered in the Session: Discussion of the elements found in the guidance document for Phase 1 material What to do at really early stages ...